Tenaya Therapeutics (TNYA): Broker Consensus Forecast

Tenaya Therapeutics (TNYA) is developing innovative gene correction methods to combat hereditary heart pathologies, anticipating future revenues from the clinical implementation of these therapies. This daily price chart, currently at 3.68, correlates with drug trial results and FDA approval. Meanwhile, high expenditures on proprietary laboratories and the current development stage temporarily limit the business's scaling capabilities.

For Tenaya Therapeutics (TNYA), whose R&D expenditures on cardiopathies are already priced in by the market, future clinical trial results will be the key growth driver. The consensus valuation trend on GURU.Markets reflects the arithmetic mean of investment bank target prices, forming an objective fundamental value model of the asset and allowing investors to track the pace of analyst expectation revisions between reporting periods.